Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Tao Hou,Shun Jiang,Yapeng Wang,Yangchun Xie,Haixia Zhang,Yeqian Feng,Fang Ma,Jin'an Ma,Xianling Liu,Chunhong Hu,Jin’an Ma

DOI: https://doi.org/10.3389/fonc.2020.608300

IF: 4.7

2020-12-21

Frontiers in Oncology

Abstract:Background The immune checkpoint inhibitors (ICIs) have achieved great success in the treatment of non-small cell lung cancer (NSCLC) patients. However, the response rate is low. The molecular mechanism involved in the effectiveness of ICIs remains to be elucidated. Methods ATRX mutation incidence among human cancers was analyzed from TCGA database. Atrx-deficient Lewis lung cancer cell line (LLC-sgAtrx) was established via AAV-CRISPR. Subcutaneous and metastasis models were established by subcutaneous and intravenous injection of LLC-sgAtrx and LLC-sgNTC cells into female C57BL/6 mice. The mice were treated with anti-PD1, anti-CLTA4 or Rat IgG2a. Tumor volume was determined by Vernier calipers and the IVIS imaging system. The proportions of CD3+ T cells, CD45+ immune cells, and the expression of pMHC I and PDL1 were determined by flow cytometry. The T cell cytotoxicity was determined by co-culture experiment. Results TCGA data showed that Atrx is a tumor suppressor mutated at high frequency among various human cancers. The tumor volume of mice bearing LLC-sgAtrx was significantly shrinked and the median survival of mice was significantly longer after anti-PD1 and anti-CTLA4 treatment. Flowcytometry results showed that Atrx deficiency increase the penetration of CD3+ T cell into the tumor microenvironment and enhanced antigen presentation after IFNγ stimulation. Additionally, the tumor cells with Atrx deficiency were more easily to be damaged by T cells under IFNγ stimulation. Conclusion The present study demonstrated that Atrx deficiency sensitize lung cancer cells to ICIs by multiple mechanisms. And ATRX may serve as a promising biomarker for ICIs which helps patient stratification and decision making.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: to explore whether alpha - thalassemia/mental retardation X - linked (ATRX gene mutation) can improve the sensitivity of non - small cell lung cancer (NSCLC) to immune checkpoint inhibitor (ICIs) treatment and to explore its potential mechanisms. Specifically, the researchers hope to experimentally verify the role of ATRX gene mutation in NSCLC and how this mutation affects T - cell infiltration, antigen - presenting ability and T - cell killing activity in the tumor microenvironment, thereby providing new biomarkers for patient stratification and decision - making in ICIs treatment.

The main conclusion of the paper is: the deletion of the ATRX gene can significantly improve the sensitivity of NSCLC to ICIs, which is mainly achieved by increasing T - cell infiltration in the tumor microenvironment, enhancing the antigen - presenting ability under IFN - γ stimulation and increasing the T - cell killing activity. Therefore, ATRX may serve as a promising biomarker for ICIs treatment, which is helpful for patient stratification and treatment decision - making.